NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $0.79 +0.00 (+0.52%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$0.80 +0.01 (+1.21%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Invivyd Stock (NASDAQ:IVVD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Invivyd alerts:Sign Up Key Stats Today's Range$0.77▼$0.8450-Day Range$0.77▼$1.5152-Week Range$0.48▼$3.07Volume2.45 million shsAverage Volume5.99 million shsMarket Capitalization$232.01 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. Read More Invivyd Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreIVVD MarketRank™: Invivyd scored higher than 71% of companies evaluated by MarketBeat, and ranked 168th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingInvivyd has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInvivyd has a consensus price target of $8.00, representing about 915.9% upside from its current price of $0.79.Amount of Analyst CoverageInvivyd has only been the subject of 3 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.50) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.61% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Invivyd has recently decreased by 20.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.46 News SentimentInvivyd has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Invivyd this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Invivyd to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders12.25% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IVVD Stock News HeadlinesInvivyd (NASDAQ:IVVD) Receives "Buy" Rating from BTIG ResearchJuly 7, 2026 | americanbankingnews.comInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAJuly 6, 2026 | markets.businessinsider.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.July 14 at 1:00 AM | Paradigm Press (Ad)IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA ApprovalJuly 6, 2026 | finance.yahoo.comInvivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-DownJuly 6, 2026 | quiverquant.comQInvivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAJuly 6, 2026 | globenewswire.comInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive OfficerJune 29, 2026 | globenewswire.comSee More Headlines IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $2.47 at the start of the year. Since then, IVVD shares have decreased by 68.1% and is now trading at $0.7875. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) announced its earnings results on Thursday, May, 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.05. The business had revenue of $13.74 million for the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative trailing twelve-month return on equity of 53.48% and a negative net margin of 138.90%. Read the conference call transcript. When did Invivyd IPO? Invivyd (IVVD) raised $309 million in an initial public offering on Friday, August 6th 2021. The company issued 18,200,000 shares at $16.00-$18.00 per share. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invivyd own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/14/2026Today7/14/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 IVVD's financial health is in the Yellow zone, according to TradeSmith. IVVD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVVD CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Invivyd$8.00 High Price Target$10.00 Low Price Target$2.00 Potential Upside/Downside+915.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.49 million Net Margins-138.90% Pretax Margin-138.90% Return on Equity-53.48% Return on Assets-41.56% Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.47 Sales & Book Value Annual Sales$53.43 million Price / Sales4.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.76Miscellaneous Outstanding Shares294,610,000Free Float258,518,000Market Cap$232.01 million OptionableOptionable Beta0.67 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:IVVD) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IVVD Stock Alerts